Angelini Pharma has signed a definitive agreement to acquire Catalyst Pharmaceuticals for a total equity value of nearly $4.1bn.

Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy pill is offering a route to greener financial pastures.

Novartis has begun construction on its new 46,000ft² RLT manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.

Gilead’s HIV portfolio was a strong growth area for the company in Q1 2026. Credit: Tada Images / Shutterstock.com. Gilead Sciences has secured a good start to 2026 with its human immunodeficiency ...

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.

Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices on a spending basis across 15,800 products.

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

This deal aligns with GSK's focus on addressing the complications of obesity, while restocking its pipeline amid key patent expiries.

Regeneron raised GAAP gross margin on net product sales to 79% to 80% from 77% to 78%. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting ...

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

Autonomous labs guided by AI can operate with increasing independence and are beginning to outperform human researchers.